The impairment and wider loss are non-cash and non-operational for the GTx-104 program, which remains the sole value driver. The $10M financing removes near-term dilution risk and extends runway through 2028, but the stock remains a binary play on NDA resubmission timing and FDA outcome. Monitor progress on manufacturing remediation and stability data milestones for the next catalyst.
Price Chart
Executive Summary
Grace Therapeutics reported Q1 2027 results with a net loss of $15.8M ($0.91/share), significantly wider than the $3.4M loss in the prior year quarter, driven by a $13.5M impairment of IPR&D for deprioritized assets GTx-101 and GTx-102. The company raised $10M in a private placement, extending cash runway through end of calendar 2028, and continues to work toward NDA resubmission for GTx-104 following a Type A meeting with the FDA that confirmed no clinical deficiencies in the CRL. The impairment is a non-cash charge that does not affect the GTx-104 program, but the widening loss and pre-revenue status keep the stock in a binary regulatory outcome scenario.
Key Financial Metrics
Key Facts
- Net loss of $15.8M for Q1 2027 vs $3.4M in Q1 2026, primarily due to a $13.5M impairment of IPR&D for GTx-101 and GTx-102
- Cash and cash equivalents were $22.2M as of August 11, 2026, with runway through end of calendar 2028
- Completed a $10M private placement financing with new and existing institutional investors
- Received FDA meeting minutes from Type A meeting; CRL items relate to CMC and non-clinical data, no clinical safety or efficacy deficiencies
- Dual-source manufacturing strategy underway with technology transfer to a second U.S.-based contract manufacturer
- No impairment required for GTx-104 IPR&D; fair value exceeds carrying amount
- Cash used in operations was approximately $3.2M for the quarter
Financial Impact
Net loss widened by $12.4M YoY due to $13.5M non-cash impairment; $10M private placement extends cash runway
Risk Factors
- NDA resubmission timing uncertain; depends on which manufacturing site reaches readiness first
- FDA may require additional non-clinical studies or data before accepting resubmission
- Current contract manufacturer's cGMP compliance status remains unresolved
- Pre-revenue biotech with no approved products; stock price highly sensitive to regulatory updates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-032644 |
| Document: ef20079525_8k.htm | 0001140361-26-032644 |
| Document: 0001140361-26-032644-index-headers.html | 0001140361-26-032644 |
| Document: 0001140361-26-032644-index.html | 0001140361-26-032644 |
| Document: 0001140361-26-032644.txt | 0001140361-26-032644 |
| 8-K Data (Synthetic) | 0001140361-26-032644 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 6w ago | Insider Cluster | $2.26 $2.22 | ▼ −1.77% | ▼ −2.62% | $1.93 (−14.60%) |
Aug 13, 2026 10w ago | 8-K | $2.07 $2.16 | ▲ +4.35% | ▲ +4.55% | $1.93 (−6.76%) |
Aug 13, 2026 10w ago | Press Release | $2.07 $2.16 | ▲ +4.35% | ▲ +4.55% | $1.93 (−6.76%) |
Aug 4, 2026 11w ago | Press Release | $2.14 $2.12 | ▼ −0.93% | ▼ −0.77% | $1.93 (−9.81%) |
Jul 28, 2026 12w ago | 8-K | $2.25 $2.08 | ▼ −7.56% | ▼ −6.02% | $1.93 (−14.22%) |
Jun 18, 2026 18w ago | 8-K | $2.38 $2.26 | ▼ −5.04% | ▼ −4.73% | $1.93 (−18.91%) |
Jun 18, 2026 18w ago | 8-K | $2.38 $2.26 | ▲ +5.04% | ▲ +4.73% | $1.93 (+18.91%) |
Jun 18, 2026 18w ago | Press Release | $2.38 $2.26 | ▲ +5.04% | ▲ +4.73% | $1.93 (+18.91%) |
Jun 5, 2026 20w ago | 8-K | $2.30 $2.33 | ▲ +1.30% | ▲ +1.60% | $1.93 (−16.09%) |
Apr 27, 2026 26w ago | 8-K | $2.16 $2.10 | ▲ +2.78% | ▲ +2.29% | $1.93 (+10.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers